On the HCPLive Lipid Management condition center page, resources on the topics of medical news and expert insight into lipidology can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dyslipidemia research, treatment, and drug development.
March 29th 2024
An analysis of the CLEAR Outcomes trial suggests bempedoic acid was well-tolerated in Hispanic/Latinx and non-Hispanic/Latinx individuals with statin intolerance.
Coronary Heart Disease Risk Among Antipsychotics
November 21st 2008Certain antipsychotics, particularly olanzapine and quetiapine, are associated with an increased risk of coronary heart disease (CHD), whereas others—like perphenazine, risperidone and ziprasidone—lead to a decreased risk of CHD, results of a new study in the Journal of Schizophrenia Research show.
Thoracic and abdominal aorticatherosclerosis
It was not until Virchow identified the cellular contributions to thrombosis that physicians began to visualize arteries as dynamic tissues.
Lipoprotein particle numbers: A better index of coronary events than lipoprotein cholesterol?
September 17th 2008In a case-control substudy of the Veterans Affairs High-Density Lipoprotein Intervention Trial, therapy with gemfibrozil was shown to reduce the total number of low-density lipoprotein (LDL) particles, especially small, more oxidizable LDL particles, which was associated with a reduced risk of coronary heart disease (CHD) events. Gemfibrozil also increased small-sized high-density lipoprotein particle numbers, which also correlated with a decrease in CHD events. Notably, these changes in particle numbers were not associated with significant changes in lipoprotein cholesterol concentrations, which current guidelines have made the principal target of lipid therapy.
Prevalent atherosclerosis-Choose your biomarker
Circulating biomarkers have been used in cardiovascular medicine as predictors of incident or prevalent disease.
Alcohol consumption in men with hypertension
September 10th 2008We assessed the association between the incidence of coronary heart disease and alcohol consumption among hypertensive men enrolled in the Health "Professionals" Follow-Up Study. Moderate alcohol consumption (1 to 2 drinks per day) was associated with a lower risk of myocardial infarction, as in the general population, but was not associated with the risks of stroke, total mortality, or mortality from cardiovascular causes. These results show that men with hypertension who drink moderately may not need to change their drinking habits.
One drug, so many off-target beneficial effects?
The background required for assessing this paper by Hanefeld and Forst is derived from clinical studies using statin and peroxisome proliferator-activated receptors (PPAR)γ agonists.
A total of 114 patients with an intermediate pretest likelihood of coronary artery disease were evaluated with both multislice computed tomography (MSCT) and myocardial perfusion imaging (MPI). Results showed that in the majority of cases, a normal MSCT scan was associated with normal perfusion. However, only half of patients with significant stenoses showed abnormal perfusion. Accordingly, MPI and MSCT are intrinsically different techniques and appear to be complementary rather than overlapping as they provide information on atherosclerosis versus ischemia, respectively.
Diabetes and inflammation influence the development of atherosclerosis. We performed a study that showed the inflammatory markers high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 were lowered with the use of fenofibrate, simvastatin, and combination therapy. The anti-inflammatory effects were most pronounced among patients with elevated baseline inflammatory markers. Combination therapy significantly altered lipid concentrations and exerted a greater positive effect on low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides than monotherapy with either drug.